**Name of Journal: *World Journal of Cardiology***

**ESPS Manuscript NO: 26907**

**Manuscript Type: Review**

**Novel concepts in radiation-induced cardiovascular disease**

Cuomo J *et al*. Radiation-induced cardiovascular disease

**Jason R Cuomo, Gyanendra K Sharma, Preston D Conger, Neal L Weintraub**

**Jason R Cuomo**, **Neal L Weintraub**, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States

**Gyanendra K Sharma, Preston D Conger**, Department of Medicine, Division of Cardiology, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Supported by** the National Institutes of Health to Neal L Weintraub, Nos. HL11264, HL126949, and AR070029.

**Conflict-of-interest** **statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Neal L Weintraub, MD,** Department of Medicine, Medical College of Georgia at Augusta University, 1459 Laney Walker Blvd., Augusta, GA 30912, United States. [nweintraub@augusta.edu](mailto:nweintraub@augusta.edu)

**Telephone:** +1-706-7216164

**Fax:** +706-7219799

**Received:** April 29, 2016

**Peer-review started:** April 29, 2016

**First decision:** June 17, 2016

**Revised:** July 14, 2016

**Accepted:** July 29, 2016

**Article in press:**

**Published online:**

**Abstract**

Radiation-induced cardiovascular disease (RICVD) is the most common nonmalignant cause of morbidity and mortality among cancer survivors who have undergone mediastinal radiation therapy (RT). Cardiovascular complications include effusive or constrictive pericarditis, cardiomyopathy, valvular heart disease, and coronary/vascular disease. These are pathophysiologically distinct disease entities whose prevalence varies depending on the timing and extent of radiation exposure to the heart and great vessels. Although refinements in RT dosimetry and shielding will inevitably limit future cases of RICVD, the increasing number of long-term cancer survivors, including those treated with older higher-dose RT regimens, will ensure a steady flow of afflicted patients for the foreseeable future. Thus, there is a pressing need for enhanced understanding of the disease mechanisms, and improved detection methods and treatment strategies. Newly characterized mechanisms responsible for the establishment of chronic fibrosis, such as oxidative stress, inflammation and epigenetic modifications, are discussed and linked to potential treatments currently under study. Novel imaging modalities may serve as powerful screening tools in RICVD, and recent research and expert opinion advocating their use is introduced. Data arguing for the aggressive use of percutaneous interventions, such as transcutaneous valve replacement and drug-eluting stents, are examined and considered in the context of prior therapeutic approaches. RICVD and its treatment options are the subject of a rich and dynamic body of research, and patients who are at risk or suffering from this disease will benefit from the care of physicians with specialty expertise in the emerging field of cardio-oncology.

**Key words:** Radiotherapy; Radiation; Cardiovascular; Atherosclerosis; Cardiomyopathy; Pericarditis; Valvular; Hodgkin; Breast cancer; Radiation fibrosis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Radiation-induced cardiovascular disease is a common complication of mediastinal radiotherapy and often occurs years or decades after treatment. It most commonly manifests as chronic pericarditis, cardiomyopathy, and valvular or coronary heart disease. Its pathophysiology is chiefly that of radiation fibrosis, fueled by chronic states of inflammation and oxidative stress. Conventional risk factors impose additive risk to these patients and must be addressed as early as possible. Development of more sensitive imaging modalities is enabling detection at earlier stages of the disease and creating opportunities for novel treatment strategies. Percutaneous interventions have an increasing role in the treatment of symptomatic vascular and valvular disease.

Cuomo JR, Sharma GK, Conger PD, Weintraub NL. Novel concepts in radiation-induced cardiovascular disease. *World J Cardiol* 2016; In press

**INTRODUCTION**

Mediastinal radiotherapy (RT) has been successfully used to decrease mortality and recurrence of a number of thoracic malignancies for decades, particularly early Hodgkin’s lymphoma (HL) and breast cancer. Thanks to advances in chemotherapeutics and radiation oncology, HL is now eminently curable, with 20-year survival approaching 80%[1], while 15-year breast cancer survival is nearing the same threshold[2]. Increased longevity has unintended consequences, however, including radiation-induced cardiovascular disease (RICVD). Where the heart was once thought to be insensitive to radiation, RICVD is now known to be the chief non-malignant cause of death in these patients, responsible for between one-quarter and one-third of their mortality[1,3-5]. The intervening decades have witnessed significant decreases in the amount of radiation to which patients are exposed, but injury to the pericardium, myocardium, valvular architecture, and vasculature continue to impose significant challenges to patients and clinicians entrusted with their care. Here, we will briefly review the epidemiology and basic characteristics of the cardinal types of RICVD, focusing on emerging concepts in the pathophysiology, prevention, and treatment of this disease.

**EPIDEMIOLOGY AND BASIC CHARACTERISTICS**

The epidemiology of RICVD is complicated by the continual improvements in radiation dosimetry and shielding that tend to reduce cardiovascular exposure and the latent effects of radiation, which take years or decades to manifest. Thus, RICD is an inherently dynamic disease process, and while clinicians continue to cope with radiation-induced comorbidities afflicted by older and higher-dose radiation regimens, data derived from patients treated decades ago will tend to overestimate incidences and morbidities, etc., of newly evolving cases. Updated epidemiologic data is therefore of critical importance to inform both patients and clinicians. Several large studies have been published over the last few years that analyzed the outcomes of RT administered between one and four decades ago. In the following section, these data will be presented in reference to the four cardinal radiation-induced cardiovascular pathologies, as well as a brief overview of the gross anatomic and histopathologic derangements known to occur over the given timelines and at the described doses.

***Acute and chronic pericarditis***

Radiation-induced pericarditis is the earliest form of RICVD to occur following mediastinal radiation. It may occur in either of two forms, early and acute or delayed and chronic, which should be regarded from a histopathological standpoint as two distinct disease entities. As an early complication of very high dose radiation, early pericarditis is extremely rare today due to implementation of dose reducing techniques. It occurs either during RT or in the days or weeks after in response to irradiation in excess of the “tolerance dose” of the organ, which is variably described as a mean heart dose of greater than 36 or 40 Gy, or a > 50 Gy dose administered to > 30% of the heart[6-8]. The effect of these doses on histopathology is profound in the short-term. In the acute setting, the pericardium becomes porous, resulting in a neutrophilic infiltrate and collection of a high-protein exudate[9]. Nearly half of affected patients develop hemodynamically-significant effusions, although in most cases they are self-limited. The development of apparently benign pericardial effusions in the acute stage may predispose the patient to chronic pericarditis of delayed onset, however[10].

Chronic pericarditis is the most common cardiac complication of radiation therapy, observed in some 70%-90% of necropsy cases[11,12]. The effect is highly dose-dependent, with incidence increasing from < 10% to > 50% as the total dose is increased from 50 to 60 Gy[7]. The incidence of symptomatic chronic, delayed pericarditis has decreased dramatically since the 1970s, falling from 20% to 2.5% with the application of just a few of the radiation-sparing techniques that are used today[13]. Nevertheless, even the low-dose radiation to which contemporary cohorts are exposed increases the incidence of chronic pericarditis by a factor of 1.6 when comparing patients undergoing left- *vs* right-sided RT[14]. This finding suggests that through the early 2000s, breast cancer survivors were accruing excess risk of chronic pericardial disease despite modern dose-schedules.

The time to onset of symptoms in chronic pericarditis can range from three months to over a decade, with one year being the median[8]. In the months prior to presentation, these patients will experience fibrous thickening of the pericardium and replacement of pericardial fat by collagen[11].In nearly 20% of cases, pericardial thickening is severe enough to cause a chronic constrictive pericarditis[15], which, when it becomes symptomatic, does so much later, requiring pericardiectomy at a median of 11 years after RT according to one recent study[16].

***Radiation-induced cardiomyopathy***

According to the latest epidemiologic data, radiation-induced cardiomyopathy (RICM) occurs at a 40-year cumulative incidence rate of 24.8%, though most of these cases evolve following a distinct cardiac insult such as valvular disease or myocardial infarction (MI)[17]. The risk of RICM increases after 5 years, but it can evolve decades after initial RT[18]. Higher doses of radiation exposure are required to instigate this level of injury; rat hearts display a tolerance dose of 15-20 Gy[19], whereas the tolerance dose of human myocardium is approximately 40 Gy[7]. That said, asymptomatic myocardial perfusion defects have been detected as soon as 6 mo following irradiation at the much lower mean heart radiation doses used in the contemporary treatment of breast cancer[20]. In the latter study, defects were observed in about 40% of patients within two years, suggesting that RICM will continue to be a significant late adverse effect of RT in the coming decades despite reductions in radiation exposure.

Pathologically, RICM is characterized by inflammation followed by the development of a diffuse, patchy interstitial fibrosis of the myocardium, and effacement of the peri-myocyte endothelium[21]. Perfusion defects can often be detected by nuclear medicine studies in the early years following RT. They lie in the irradiated regions and do not follow the major coronary artery distributions, reinforcing the view that microvascular injury is central to this pathology[22]. As the heart becomes fibrotic it loses compliance, resulting in diastolic dysfunction[23]. Wall-motion abnormalities follow, occurring in 18% and 29% of patients in their second and third decades after RT, respectively, *vs* 5% in non-irradiated age-matched subjects in the Framingham population[24]. In the same study, a decline in left ventricular mass and wall thickness was also noted, which runs contrary to the trend seen in normal aging. Impairment of systolic function occurs last and should be considered a sign of late RICVD.

***Valvular heart disease***

The natural history of valvular heart disease (VHD) varies with radiation dose and, by extension, the decade in which the patient was treated. A study of HL survivors irradiated under obsolete protocols between 1965 and 1995 revealed 13- and 30-year cumulative incidences of 10% and 20%, respectively. Prior history of RT increased the risk of VHD for these patients 7-fold[18]. Unfortunately, VHD progresses in more than 30% of irradiated HL survivors throughout the second and third decades following treatment in this dose range[25]. More recently, researchers at the Netherlands Cancer Institute found a stepwise decrease in 30-year cumulative incidence of VHD corresponding to diminishing doses of RT, from 12.4% at doses greater than 40 Gy to 3.0% at doses less than 30 Gy[26]. At the lower end of this steep dose-response curve, where most treatment regimens are dosed currently, the absolute difference in 30 year VHD risk in irradiated *vs* non-irradiated patients was estimated to be 1.4%. Nevertheless, patients treated in past decades will continue to experience higher rates of VHD in the coming decades, particularly those exposed to high doses of radiation in the remote past.

With respect to the gross pathology of VHD, the earliest change appears to be the formation of valvular retractions and accompanying regurgitation preferentially involving the mitral and aortic valves, occurring within the first 10 years. The progression to fibrotic thickening and calcification of the valves occurs much later, with stenosis often appearing 20 years after RT[25].Mitral and aortic valve regurgitation are the most common defects, and when stenosis occurs, it most commonly afflicts the aortic valve (Figures 1 and 2).

***Radiation-induced coronary heart disease***

Radiation-induced coronary heart disease (CHD) is currently the most active area of RICVD research. Until the 1990s, its existence was controversial, but it has been unmasked by longer survivorships and mass epidemiological studies in the ensuing decades. The disease burden it imposes is significant, in part because it can be induced by radiation doses that are well less than 10% of the tolerance dose of other cardiac tissues; thus, it more frequently complicates the course of breast cancer treatment than other forms of RICVD[7]. A large case control study of breast cancer survivors in Denmark and Sweden undertaken in 2013 found that the risk of a major CHD event begins to increase within the first 5 years post-treatment and continues to significantly exceed that of the general population through at least 20 years of follow-up[27]. These patients experienced increased risk of angina pectoris, MI, and sudden cardiac death despite having been treated with a modest mean heart dose of 3.6 Gy RT between 1958 and 2001. Patients receiving radiation doses of < 2 Gy, 2-4 Gy, 5-9 Gy and > 10 Gy experienced dose-dependent excess risks of 10%, 30%, 40% and 116%, respectively, *vs* carefully matched controls. Another large study of women in Denmark and Sweden (*n* = 35000) comparing incidences of MI in breast cancer survivors observed an incidence ratio of 1.22 in patients undergoing left-sided *vs* right-sided RT[14]. In that study, the mean heart dose in patients with right-sided tumors was 2.7 Gy (*vs* 6.3 Gy for left-sided tumors), so the incidence ratio likely underestimates the true excess risk of RT compared with the general population. Concerning higher-dose radiotherapy, a 2015 study from the Netherlands Cancer Institute found a 40-year cumulative CHD incidence of 22.9%, amounting to a 4- to 7-fold increase in risk and 475 excess cases per 10000 person-years as compared to the general population[18].

The gross pathology of radiation-induced CHD differs from that of ordinary CHD in certain key respects. Radiation-induced coronary artery lesions tend to be longer and to preferentially involve the ostium, and they are therefore more challenging to treat percutaneously[28-30]. The left anterior descending (LAD) coronary artery is often preferentially involved because of its proximity to the radiation field (Figure 3).

This is particularly so in treatment of breast cancer where, while average heart doses are currently 1-5 Gy, the maximum LAD doses may exceed 20 Gy[31]. With respect to histopathology, these lesions tend to differ little from those of ordinary atherosclerosis and are characterized by intimal thickening, lipid accumulation, inflammation, and thrombosis[13]. They are often, however, somewhat more fibrous, with reduced lipid content, and the vessels involved tend to be more friable[23]. Other great vessels are likewise subject to radiation-induced friability, and the aorta and carotid artery have been known to rupture following RT on occasion[21]. Moreover, the carotid arteries have been noted to demonstrate early and rapid formation of unstable plaques following irradiation in rat models[7].

**PATHOPHYSIOLOGY**

Our basic understanding of the pathophysiology of RICVD has changed little since the seminal work of Fajardo *et al*[9,10] in the 1960s and 70s. It has long been understood that irradiated pericardial, myocardial, endocardial, or endothelial tissue is prone to inflammation, which later results in tissue fibrosis and loss of capillaries at the microvascular level[10].Until the early 2000s, studies in animal models and *in vitro* human tissues primarily focused on the mechanisms by which these changes occurred in the acute setting. Since the turn of the century, emphasis has shifted to the manner in which the acute inflammatory state gives way to chronic, pathological fibrosis. This section will begin with an overview of the inflammatory response, followed by a discussion of novel research into the mechanisms by which chronic and long-lasting profibrotic states become realized.

***Acute inflammation***

The mechanisms of tissue injury in the acute setting of radiation-induced pericarditis, valvular disease, cardiomyopathy and coronary disease are essentially the same and appear to be largely mediated by damage to the endothelium. Whether in the visceral pericardium, the highly vascular myocardium - which has a capillary density of 2800 capillaries per mm2 as compared to 350/mm2 in skeletal muscle[32] - or the small and medium-sized vessels that perfuse the heart, the endothelium is site of initial damage. Within minutes of irradiation, endothelial cells become hyperpermeable. By the passing of the second hour, the endothelium has begun to display membrane-bound molecules such as E- and P-selectin, which are involved in leukocyte cell rolling, and ICAM-1 and PECAM-1, which are involved in leukocyte arrest and transmigration[7].

These activities stimulate the neutrophilic response that predominates acutely, with these first-responders releasing pro-inflammatory cytokines such as tumor necrosis factor, monocyte chemotactic factor, and interleukin (IL)-8, resulting in recruitment of additional inflammatory cells[33]. While this pro-inflammatory activity of granulocytes and other immune cell types was once thought to be the chief, if not the sole cause of acute inflammation and fibrosis[34], inflammatory chemokine secretion by the endothelium itself has garnered much research interest in recent years. *In vitro* studies of cultured human microvascular endothelial cells have confirmed a radiation-induced increase in IL-6, IL-8, human fibroblast growth factor, and adhesion molecules such as ICAM-1, in the absence of immunologic cells. This suggests an immunologic and secretory functionality of the vascular endothelium that contributes to the pro-inflammatory state[35,36].

Finally, the contribution of coagulation to this acute endothelial inflammatory response merits consideration. The presence of early fibrin deposits in the capillary networks within radiation-exposed myocardium was noted in the initial studies of RICVD[37]. This is now known to result from impaired endogenous fibrinolysis, likely due in part to thrombomodulin inhibition by transforming growth factor-beta (TGF-β), and perhaps by RT itself[38]. The role of hyperacute coagulation in the eventual development of chronic fibrosis is as yet unknown. Certain coagulation factors such as thrombin, however, can induce endothelial secretion of chemokines such as IL-8 and monocyte chemoattractant peptide, which in turn promote chemotaxis of neutrophils and expression of adhesion molecules to upregulate inflammation[39,40].

***Fibrosis***

Fibrosis is the chief process by which chronic radiation damage occurs. At the biochemical level, fibrosis is the result of abnormal deposition of collagenous extracellular matrix (ECM) by activated myofibroblasts. The manner in which this comes about is still the subject of investigation. Cardiovascular fibrosis is a chronic but dynamic process that is propagated by pro-fibrotic cytokines, phenotypic alterations in various cell types, and the presence of chronic hypoxia and oxidative stress. Central to this process is the terminal differentiation of fibroblasts into myofibroblasts, which secrete more type I and III collagen, as well as alpha-smooth muscle actin, another ECM protein, than do their progenitors[41]. Stimuli that may lead to myofibroblast formation in radiation injury include pro-inflammatory cytokines, matricellular signals, and epigenetic reprogramming.

Pro-fibrotic cytokines such as platelet-derived growth factor (PDGF), IL-13, IL-4, and TGF-β are secreted in abundance by neutrophils and other immune cell types recruited to irradiated tissues. TGF-β in particular has many pro-fibrotic activities, including both the promulgation of myofibroblasts and the inhibition of collagenases[40,41]. IL-13 and IL-4 are chiefly secreted by Th2 lymphocytes and act at a variety of tissues to stimulate collagen deposition[34,42]. They have chiefly been studied in the context of hepatic and pulmonary fibrosis but are active in vascular tissues as well[43-45].

Matricellular signals also contribute to pro-fibrotic phenotypic changes. One such ECM protein that may constitute a future therapeutic target in RICVD is connective tissue growth factor (CTGF), which is induced by TGF-β and promotes differentiation of mesenchymal cells and resident fibroblasts into myofibroblasts[46-48]. Moreover, CTGF can continue to stimulate myofibroblasts to secrete ECM even after TGF-β levels have normalized, thus perpetuating fibrosis long after the initial insult has passed[49,50]. Indeed, knockdown of CTGF expression in human cardiac fibroblasts decreased fibroblast growth, and CTGF inhibition was shown to reverse fibrosis, decreasing vascular stiffness and myocardial dysfunction in rodent models, though this finding has not yet been replicated in irradiated models[51].

As terminally-differentiated cells, myofibroblasts are destined to undergo apoptosis rather than mitosis during normal wound healing. This typically results in a self-limited and acellular scar[52]. They persist in radiation-induced fibrosis, however, and a growing body of evidence links this to epigenetic reprogramming. DNA methylation is the most studied mode of epigenetic modification in radiation-induced fibrosis[53]. In murine fibroblasts, expression of the α-smooth muscle actin gene, a marker of myofibroblast differentiation, was reported to be regulated by methylation of CpG islands in the gene promoter[54]. Moreover, TGF-β-induced suppression of DNA methyltransferase expression contributed to induction of the α-smooth muscle actin gene and thus myofibroblast differentiation. In contrast, induction of α-smooth muscle actin expression during hypoxia was reported to be associated with DNA hypermethylation and upregulation of DNA methyltransferases[55]. This and other studies suggest that regulation of fibroblast differentiation via epigenetic DNA methylation is complex and context-specific[56,57].

Hypermethylation of genes involved in apoptosis has been observed following irradiation and is associated with decreased cell death, which could promote fibrosis[58]. Moreover, the patterns of DNA methylation predating irradiation may be a determinant of radiation fibrosis. Human dermal fibroblasts taken from patients who later developed radiation-induced fibrosis demonstrated decreased methylation of two intragenic sequences of the diacylglycerol kinase alpha gene, a regulator of fibrosis-associated signaling pathways[59]. Moreover, decreased DNA methylation at these sites correlated with future development of profibrotic fibroblast activation, highlighting the potential prognostic value of epigenetic modifications with respect to radiation-induced fibrosis. Methylation-inhibiting agents may hold promise in the treatment or prevention of RICVD and are currently in clinical trials. Aberrations in two other modes of epigenetic modulation - microRNA activity and histone modifications - have been linked to fibrosis in various tissues, including the heart (for a detailed review, see Weigel *et al*[53]), but we know very little about their contributions to RICVD at this time.

***Oxidative stress***

In addition to directly inflicting cellular injury, radiation-induced oxidative stress is thought to play a key role in the transition from acute inflammation to chronic inflammation and fibrosis[60]. Reactive oxygen species (ROS) are acutely generated by the direct action of radiation and subsequently produced by both macrophages and the inflamed endothelium, which are replete with ROS-generating enzymes[61]. Macrophages produce large quantities of superoxide and nitric oxide, the latter *via* inducible nitric oxide synthase[62,63]. Superoxide and nitric oxide react to form peroxynitrite, a toxic source of free radical injury[64]. The decreased availability of nitric oxide resulting from this conversion promotes vascular dysfunction and tissue hypoxia, which further exacerbates oxidative stress[63].

Once initiated, oxidative stress propagates inflammation through several mechanisms. For example, oxidative stress promotes chemotaxis by upregulating expression of adhesion molecules such as ICAM[65] and by increasing monocyte chemotactic protein-1 and TNF-α levels[66]. Moreover, ROS increase thrombin activity by inactivating thrombomodulin, potentially promoting inflammation as previously described[67]. Though a causal link between radiation-induced oxidative stress and inflammatory cytokine production is difficult to establish, anti-oxidant studies are informative. For example, administration of alpha-lipoic acid prior to irradiation was reported to decrease local levels of IL-1, IL-6, and metalloproteinases in mice[68], while melatonin decreased levels of IL-1, TNF-α, and TGF-β[69].

ROS also promote inflammation *via* their complex interaction with NF-κB, a transcription factor responsible for such critical functions as immune regulation and cell survival. In the setting of RICVD, NF-κB activation by ROS results in increased adhesion molecule, cytokine, and chemokine production[70]. An association with fibroblast stimulation and collagen deposition has also been demonstrated. Importantly, NF-κB upregulation was detected from week 4 through week 500 post-irradiation in small vessels of the neck in humans[71], suggesting that NF-κB might be a critical element in the transition from acute inflammation to chronic fibrosis (Figure 4).

Free radicals produced by macrophages result in increased pro-fibrotic TGF-β production in irradiated animals[72]. This change is preceded by tissue hypoxia, which follows in RICVD from capillary effacement and diminished perfusion. Additionally, ROS have been reported to cleave TGF-β from its anchorage sites in the ECM, which in turn promotes myofibroblast differentiation and ECM deposition[61]. Lastly, free radicals establish a preference for the Th2 lymphocyte phenotype over the Th1 response[73,74], thus skewing the lymphocyte population towards those that preferentially secrete IL-4, IL-13, TGF-β, *etc*. These and other chemical signals act in concert to stimulate myofibroblast hyperactivity and disordered ECM deposition.

**PREVENTION**

The cardiovascular morbidity and mortality of RT can be forestalled through primary prevention, which consists of dose reduction and radioprotection, and secondary prevention, which consists of screening and radiomitigation. No pharmaceuticals are currently approved by the FDA for either purpose, although Amifostine, a scavenger of free radicals, was recently approved for the reduction of radiation-induced xerostomia[75]. This discussion will therefore focus on dose-reduction, screening, and risk modification, ending with a brief discussion of novel uses of existing pharmaceuticals, such as statins and ACE inhibitors.

The most important means of prevention is reduction in radiation exposure. Advances in radiation oncology have resulted in decreases in absolute 15-year cardiac mortality from 13% in the mid-1970s to 5.8% in the late 1980s for breast cancer survivors[76]. Meanwhile, the incidence of major CHD events in HL survivors has remained roughly unchanged during the same period despite dramatic increases in utilization of cardiotoxic chemotherapeutics[18]. Recent reviews have dealt with the techniques by which this has been achieved[77,78]. Some of these strategies involve manipulating the patient so as to exclude as much of the myocardium from the treatment field as possible; for instance, use of breast boards or prone positioning may reduce the volume of myocardium traversed by the radiation beam. Likewise, deep inspiration and inspiratory gating are two techniques by which radiation oncologists exploit the heart’s tendency to fall inferiorly and posteriorly out of the radiation field. Perhaps the most important advancement is the use of intensity-modulated RT, in which 3-D CT images are used in conjunction with multileaf collimators that can be manipulated to deliver radiation beams that conform closely to the shape of the tumor. With respect to HL, reductions in radiation exposure are mainly attributable to dose fractionation, and to the shift from mantle field radiation, which encompasses much of the neck, mediastinum, and axilla, to more limited, involved fields[79]. All of these techniques presuppose superior imaging and software technologies that deliver radiation more accurately - often to within several millimeters of the desired target - and with much smaller margins than were used in the in the previous century.

Despite these improvements, excess risk of morbidity and mortality persist. It is therefore imperative that cardio-oncologic care be coordinated prior to initiation of RT for the establishment of appropriate cardiac baselines and for continued surveillance throughout the patient’s lifetime. The younger the patient is at time of treatment, the more critical the need for surveillance, as both their relative risk of RICVD and their survivorship with respect to cancer are greater[18]. Cardio-oncologic care should begin with risk factor modification, as conventional CHD risk factors are particularly hazardous in this population. Indeed, traditional risk factors have been shown to more than double the relative risk of CHD events in these patients as compared to matched patients in the general population[80]. Thus, hypertension, hyperlipidemia, and diabetes mellitus should be managed aggressively, and patients should be counseled regarding smoking cessation, weight loss, and exercise where appropriate.

***Screening and detection***

The cardiac morbidity and mortality associated with RT can be reduced if treated early, which justifies the need for screening and early detection of RICVD[81]. Prospective data regarding cost- and risk-benefit analyses with respect to screening are lacking, however. Although evidence-based guidelines are unavailable, several expert consensus statements have been derived based on the available randomized trials and epidemiological studies. In 2014, the American College of Radiology Appropriateness Criteria Report made a case for the importance of surveillance but stopped at recommending personalization[82]. The expert panel of the National Comprehensive Cancer Network (NCCN) called for aggressive management of cardiovascular risk factors with annual blood pressure and biannual lipid screening in their expert consensus statement released in 2015. They also recommended considering a baseline stress test or echocardiogram every 10 years after treatment[83]. Some experts have proposed that irradiation should be considered an additional CHD risk factor in the presence of hypertension, hyperlipidemia, or diabetes[81].

Finally, the most rigorous set of screening recommendations came from the European Association of Cardiovascular Imaging and the American Society of Echocardiography in 2013, which recommend aggressive risk factor modification and yearly physician visits. The statement went further, however, recommending baseline echocardiography prior to RT, followed by repeat echocardiography 10 years after treatment and every five years thereafter in heart-healthy patients[84]. For patients with one or more conventional risk factors, screening echocardiography was recommended in the fifth year after treatment, and noninvasive stress testing was recommended 5-10 years after treatment and at 5-year intervals, with a preference for stress echocardiography in these patients.

The prospective data supporting these statements was largely derived from a series of studies by Heidenreich *et al*[24], who screened asymptomatic HL survivors for RICVD. Their study of echocardiography in asymptomatic patients uncovered a 29% prevalence of significant valve disease in HL patients as compared to 3% in the general population[24]. Diastolic dysfunction was detected in 14% of the HL patients at a mean of 14 years post-RT[23]. While the cost-benefit ratio of screening for heart failure with preserved ejection fraction (EF) is uncertain due to the lack of effective treatment, a disproportionate number of patients thus afflicted also demonstrated stress-induce ischemia on subsequent stress echocardiogram or nuclear perfusion imaging (23%). Finally, Heidenreich *et al*[85] evaluated stress echocardiography and radionuclide perfusion imaging as screening tests for asymptomatic CHD after RT. They observed a 2.7% prevalence of severe, multivessel or proximal coronary stenosis, and a 7.5% prevalence of coronary stenosis greater than 50% at a mean 15 years after RT. The cohort overall had a documented 8% prevalence of coronary insufficiency or death. The generalizability of these data is limited by the high radiation doses employed in the cohort; the mean heart dose in the three trials was 43-44 Gy, which is much higher than most HL patients receive today. Nevertheless, these findings are likely pertinent to patients irradiated prior to the 1990s, or to more recently treated patients receiving mean heart doses greater than 35 Gy.

Thus, current literature supports use of transthoracic echocardiogram as the screening tool of choice to evaluate baseline left ventricular EF, diastolic function and VHD. Echocardiography is also important in the assessment of restrictive cardiomyopathy and constrictive pericarditis. Ultrasonographic technologies are constantly evolving, leading to improvements in the ability to detect subtle signs of RICVD disease *via* echocardiography. Using cardiac MRI as the gold standard, 3D echocardiography was reported to exhibit greater sensitivity than 2D echocardiography to detect left ventricular EFs less than 50% (53% *vs* 25%, respectively)[86]. Deformation imaging using speckle tracking or tissue Doppler velocities may be even more sensitive to detect subtle abnormalities in left ventricular function[87,88]. Reductions in systolic myocardial deformation were detected immediately and 2 mo after RT, in the absence of detectable reductions in EF[89]. Speckle tracking echocardiography demonstrated abnormal global longitudinal and global circumferential strain in 33% and 21.7%, respectively, of patients who underwent RT, while depressed EF was detected by 3D echocardiography in only 5.7% of patients at a median 22.6 years[90]. While no gold standard was applied, abnormal longitudinal strain was correlated with reduced quality of life and lower mean 6-minute walk distances, even when it was the sole abnormal finding. Thus, while reduced EF is a late finding in RICVD, abnormal strain measurements may herald early onset disease and are increasingly being incorporated into screening protocols (Figure 5).

Though it is not a first-line screening tool, cardiac MRI is helpful in evaluation of left ventricular EF and, with the addition of myocardial tagging, may be utilized for better evaluation of constrictive pericarditis. This modality is particularly well-suited to detection of the patchy fibrosis that may be associated with microvascular insufficiency even in the absence of classical ostial coronary stenosis, ischemia, or infarction[91]. The pattern of late gadolinium enhanced MRI images can help differentiate between MI, diffuse myocardial fibrosis, and constrictive pericarditis as the underlying mechanism of the cardiomyopathy[92,93].

Newer screening modalities for radiation-induced vascular disease have also been evaluated, including coronary artery calcium (CAC) imaging. In a cohort of 47 HL survivors who received a mean cardiac dose of 40.6 Gy, CAC imaging demonstrated a strong association between severity of CAC and the presence of coronary artery disease verified by angiography[94]. The proportion of patients with CAC scores of zero was much lower in the HL cohort than in the general population. Another study using CT angiography in HL survivors detected nearly twice as many atherosclerotic lesions in pre-cranial blood vessels contained within the radiation field as compared with a non-irradiated control group; the percentages of calcified *vs* non-calcified lesions were similar in the HL and control groups, suggesting that atherosclerosis, but not calcification, is a radiospecific finding[95]. Interestingly, this study also found that elevated total cholesterol, measured soon after RT, correlated strongly with later incidence of coronary artery disease. While these studies suggest a role for CT in screening for vascular disease in HL survivors, their generalization is limited by the high doses of radiation to which these older cohorts were exposed. Indeed, a larger study of CAC screening in 236, 12-year breast cancer survivors who had been exposed to lower doses of radiation did not find any excess CAC, though the duration of follow-up may have been too short to detect late occurrences[96]. Thus, CT imaging may be of greater utility in detection of CHD in cancer survivors who are in their second or third decade post-RT.

Laboratory monitoring is another important component of screening for RICVD. The importance of identification and management of hyperlipidemia in cancer survivors with a history of RT is emphasized by data showing a direct correlation between the presence of hypercholesterolemia soon after RT and atherosclerosis[95,96]. Chen *et al*[97] (2009) applied a decision-analytic model to perform a cost-benefit analysis in a hypothetical cohort of HL survivors to establish the cost-effectiveness of screening intervals for hyperlipidemia. Applying an assumed relative risk of cardiac mortality of 3.2 to a theoretical cohort that otherwise differed little from that of the general population, the optimal interval for screening for hyperlipidemia was determined to be every three years. With respect to biomarker screening, elevation of troponin-I and brain natriuretic peptide have been demonstrated in patients during and immediately following RT in a small cohort of breast or lung cancer patients[98]. A later study found subacute elevations of high-sensitivity troponin-T following RT that were dose-dependent[99]. This study also detected echocardiographic evidence of interventricular septal thickening and prolonged diastolic deceleration time in patients who experienced a greater than 30% increase in troponin levels from baseline, suggesting that elevated high-sensitivity troponin-

T correlates with subtle abnormalities of cardiac function after RT. The implications for the utility of high-sensitivity troponins in screening for future cardiac disease are unknown but may become clearer after the planned follow-up with this cohort.

***Radioprotection and radiomitigation***

As to the role of pharmaceuticals, several commonly prescribed agents are currently being evaluated in primary and secondary prevention after promising results were observed in animal trials. Statins have been studied extensively in rodent and *in vitro* human models and have shown promise through several of the mechanisms discussed in the Pathophysiologysection. Pravastatin has been found to inhibit the activity of CTGF by modulating associated proteins such as Ras-homologous (Rho) GTPases[100]. Rho-family proteins regulate cellular responses to pro-fibrotic cytokines such as TGF-β, and to oxidative stress[46]. They also increase cell adhesion and contribute to the reorganization of the ECM[100,101]. Some of the statins’ anti-fibrotic activities may also be related to attenuation of radiation-induced NF-κB activity, which depends upon activation by Rho-family GTPases[102]. Additionally, statins upregulate thrombomodulin expression in human endothelium, decreasing the pro-inflammatory activities of thrombin as described previously[103]. Lastly, atorvastatin has been found to reduce injury to and apoptosis of the vascular endothelium[104]. Notably, several trials of statins in young patients who were treated with RT are underway[105]. Although surrogate endpoints, such as detection of endothelial function and carotid intimal-medial thickness, will be employed, these studies nevertheless may begin to illuminate the role of early statin therapy in reducing the long-term risk of RICVD.

Angiotensin converting enzyme (ACE) inhibitors are another commonly prescribed class of drug with radioprotective and radiomitigating potential. Rats treated with captopril shortly after radiation of the lung demonstrated dramatically increased survival and improved vasoreactivity, as well as decreased perivascular fibrosis and inflammatory cell infiltration[106]. Similar findings with respect to the pulmonary vasculature have been reported in rats treated with ACE inhibitors two weeks after irradiation[107]. More recently, rats treated with captopril exhibited reduced diastolic dysfunction and perivascular necrosis in the left ventricle following radiation exposure[108]. Although these data are intriguing, prospective studies evaluating the efficacy of ACE inhibitors in patients undergoing RT have not been reported.

Lastly, antioxidant approaches are the subject of much investigation. Amifostine was previously mentioned in connection with its indication for treatment of xerostomia, but in a small rodent study of RICVD, this drug was found to reduce myocardial fibrosis and impairment of aortic and coronary blood flow[75]. Melatonin is also being evaluated for this use, as it is known to act both as a scavenger of free radicals and as a stimulant of antioxidants[109,110]. It was reported to reduce the development of vasculitis, myocyte necrosis, and fibrosis following high-dose radiation in a rat model[111]. These and several other antioxidant strategies such as the use of selenium[112] show promise and warrant further exploration in animal studies.

**TREATMENT**

***Acute and chronic pericarditis***

Acute pericarditis is extremely rare thanks to reductions in the mean heart dose during RT. The clinical presentation may occur during treatment or in the following weeks. In the former instance, pericarditis is typically the result of the presence of a heavy tumor burden adjacent to or extending into the pericardium, and the subsequent tumor lysis. In both instances, the presentation is similar to that of idiopathic acute pericarditis, characterized by fever, pleuritic chest pain, and a pericardial friction rub. ECG may demonstrate low QRS voltage and diffuse ST or T wave changes. Standard transthoracic echocardiography typically demonstrates a pericardial effusion. This syndrome is usually self-limited and responds to treatment with NSAIDs and colchicine, but it may progress to tamponade physiology[37]. Pericardiocentesis is indicated in the event of hemodynamic compromise.

Radiation-induced chronic pericarditis is a more unique disease entity, in that it frequently presents as fibrinous constrictive pericarditis. The most common presentation is as an incidentally discovered asymptomatic effusion, however. This type of pericarditis rarely progresses to tamponade because of its chronicity, and the presentation is similar to that of acute pericarditis. The imaging modality of choice is echocardiography in these patients, for reasons of cost, ease of use, and reproducibility. The latter advantage is critically important in the case of recurrent effusions and symptomatic constrictive pericarditis, which may help the clinician to make appropriate referral for invasive procedures[84]. Cardiac CT and MR, on the other hand, have proven to be more sensitive in the diagnosis of constrictive pericarditis owing to better visualization of pericardial thickening and calcifications. Moreover, cardiac MR is more specific in the diagnosis of constrictive pericarditis, distinguishing it from transient constriction due to active inflammation and effusive-constrictive pericarditis. This can be useful in assessing prognosis and in determining whether or not to proceed with a high-risk pericardiectomy[93].

Recurrent symptomatic effusions may require pericardiectomy, which is also the mainstay treatment of symptomatic constrictive pericarditis. While the procedure does provide benefit to irradiated patients, these patients have poor prognoses, with a 21% perioperative mortality and a 7-year survival rate of just 27%[16,113]. In one study, zero of five patients survived beyond five years[114]. Unfortunately, these mortality rates may reflect both the technical difficulties in operating on the irradiated heart and progression of other forms of RICVD that inevitably follow from large radiation exposures.

***RICM***

RICM may remain asymptomatic for years before presenting as a typical clinical heart failure syndrome with shortness of breath and other symptoms of volume overload. Diastolic dysfunction is typically the earliest imaging finding in RICM, followed by abnormalities pertaining to strain and strain rate such as discussed in the screening and detection section. Therefore, this new echocardiographic modality is optimal for establishing an early diagnosis of RICM. When a reduction in EF occurs, it is often a late finding. Cardiac MR is appropriate for use in patients with poor acoustic windows and not only detects reductions in EF, but also visualizes the inciting myocardial inflammation and fibrosis[84]. Once RICM has been confirmed, treatment should be initiated per the ACC/AHA guidelines, as there are no drugs specifically approved to treat radiation-induced myocardial inflammation or fibrosis. This is also the case with respect to implantable cardioverter-defibrillator (ICD) placement, as the indications for its use have not been specifically evaluated in RICM. As to the location of ICD implantation, it has been suggested that a sub-pectoral approach may be preferred in order to avoid instrumenting the irradiated superficial tissues[5].

In patients with biventricular heart failure due to radiation-induced restrictive cardiomyopathy, cardiac transplant may be performed as a last resort. Several case series have been published in recent years detailing the outcomes of these cases. The largest was a 2012 study of patients undergoing transplant for restrictive cardiomyopathy, which included a subgroup of 35 patients with RICM. This group demonstrated 1-, 5- and 10-year transplant survival rates of 71%, 47%, and 32%, respectively - the poorest survival rates amongst all of the subgroups[115]. A 12-subject cohort of patients transplanted for RICM reported a lower mortality, with a 5- and 10-year survival of 75% and 47%[116]. Of note, eight of these patients were transplanted for treatment of restrictive cardiomyopathy. Given the limitation in donor hearts eligible for transplantation, and the large numbers of patients currently on waiting lists, cardiac transplantation is likely to play a very limited role in patients with end-stage RICVD.

***VHD***

Little has been written about peculiarities of the clinical presentation of radiation-induced VHD. Echocardiographic studies have demonstrated that it typically begins as an asymptomatic regurgitation of the mitral and/or aortic valves, progressing to include aortic stenosis in 39% of patients[25]. Radiation-induced VHD is most commonly diagnosed after a long latent period[117] and in the context of clinical symptoms of heart failure[18], to which valvular insufficiency is either contributing or responsible. When VHD is suspected, i.e. on the basis of a new murmur, transthoracic Doppler echocardiography is the first line of investigation, with transesophageal echocardiography reserved for when the initial evaluation is non-diagnostic[84].

The frequency of radiation-induced VHD is significantly greater than seen in the general population. In a cohort of HL patients, the standardized incidence ratio for valve surgery was found to be 9.19 when compared to the estimated expected national incidence in the United States, though this may be an overestimate, as some of these patients were irradiated under older protocols[118]. Aortic valve replacement was the most common procedure in this cohort, though mitral and tricuspid valve disease may also require intervention. Crestanello *et al*[119] reported that 32% of previously irradiated patients who underwent mitral and/or tricuspid valve repair experienced severe valve deterioration, likely because of progression of radiation-induced tissue injury. In light of these findings and the known dangers of reoperation in this cohort, the authors concluded that mitral and triscupid valve replacement may be superior to repair in patients with RICVD.

Over the past several years, transcutaneous aortic valve replacement (TAVR) has proven equal or superior to surgical valve replacement in high-risk patients[120,121]. As valve technology and techniques for TAVR have evolved, favorable outcomes are now also being observed in intermediate risk patients. Approximately 5% of patients enrolled in recently published TAVR trials have a history of prior chest wall radiation, with initial favorable results[122]. However, long-term results are unavailable. Nevertheless, TAVR is likely to play an increasingly prominent role in treatment of patients with radiation-induced aortic disease given the associated surgical morbidity/mortality in this high-risk population.

***CHD***

There is currently no basis of evidence to suggest specific deviations from treatment guidelines for the medical management CHD in patients with a history of mediastinal irradiation. The increased risk of CHD in patients with a history of RT may prompt a more aggressive approach where the etiology of chest pain is in question and/or diagnostic findings are ambiguous. As always, coronary angiography is the gold standard, and clinicians should have a lower threshold to consider it in this population. On the other hand, both percutaneous interventions (PCI) and surgical revascularization are often more challenging and less effective in this population, which must be taken into account. As noted previously, coronary artery lesions tend to be proximal or ostial in this population, and may not be readily amenable to PCI. A prospective study of bare metal stent placement in HL survivors was conducted between 1993 and 2003 and revealed in-stent restenosis in 86% of irradiated patients within the first six months, with an odds ratio for this event of 21.7[123]. Moreover, revascularization of the target vessel with balloon angioplasty was required in 67% of the RT cohort at six months per coronary angiography. However, most of these patients were treated with early generation stents and single antiplatelet therapy. A larger case control study in which 36% of patients received newer drug-eluting stents, and all patients received dual antiplatelet therapy, found no difference in the rate of in-stent restenosis requiring revascularization between irradiated and non-irradiated patients[124]. Drug-eluting stents did not outperform bare metal stents in this study; nevertheless, use of newer generation drug-eluting stents is usually preferred in this population.

Surgical revascularization of the irradiated heart is often necessary, but is not without complication. Operative mortality rates of 6% have been reported, and one- and five-year actuarial survival has been estimated to be 87% and 72%, respectively[125]. Sixty-two percent of patients in the latter cohort required valve surgery concomitantly or after the initial surgery, suggesting that valvular dysfunction is a significant contributor to mortality in this population. In another, larger study of cardiothoracic surgical outcomes in irradiated patients, a dose-dependence was observed with regard to post-operative and long-term mortality data[126]. At lower doses of radiation exposure, breast cancer patients undergoing open-heart surgery were found to approach, but not reach, the levels of 4-year survival expected of the general population, while the outlook for HL patients was much worse (73%, 64% and 57% survival at 1-, 2- and 4-years, respectively). Lastly, irradiated patients often exhibit friability of the left internal mammary artery, a well-known complication encountered when that vessel lies in the irradiated field, which compromises its use as a bypass conduit and diminishes the overall benefit of bypass surgery in patients with RT.

**CONCLUSION**

Despite advancements in radiation oncology, it appears that cancer survivors treated with breast and mediastinal radiotherapy will continue to present with complicated cardiovascular problems for the foreseeable future. Further research is needed to elucidate pro-fibrotic mechanisms and identify promising therapies that can be implemented early during the course of treatment. The phenotypic shift from fibroblast to myofibroblast is a result of the complex interplay of radiation-induced oxidative stress, inflammation, cell signaling, and epigenetic modifications, which requires further study in animal models. Medications such as ACE inhibitors and statins favorably impact many of these pathways and have shown promise in animal models of RICVD; these agents are just now beginning to be tested in patients who have undergone RT. Novel imaging approaches, such as 3D echocardiography, strain imaging, and CT/MRI scanning, are enabling the detection of early-stage RICVD, which will help to better evaluate risk and facilitate future interventional trials. Evolution of PCI (*i.e*., transcutaneous valve replacement and drug-eluting stents) holds great potential for improving treatment of patients with RICVD, and these techniques are rapidly gaining favor given their encouraging outcomes and lower complication rates as compared to surgical interventions. Although evidence-based guidelines with respect to screening, prevention and treatment of RICVD are lacking, algorithms have been developed by experts in the field that favor a more aggressive approach than was typically pursued in prior decades. Coordination of care between oncologists, cardiologists, and primary care physicians for the purpose of early detection, risk factor modification and treatment provides the best hope of reducing the morbidity and mortality associated with RICVD.

**ACKNOWLEDGEMENTS**

We thank Dr. Benjamin Mazer for his assistance in the creation of our figures.

**REFERENCES**

1 **Ng AK**, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. *J Clin Oncol* 2002; **20**: 2101-2108 [PMID: 11956271 DOI: 10.1200/jco.2002.08.021]

2 **American Cancer Society**. Cancer Facts & Figures 2016. Atlanta: American Cancer Society, 2016. Available from: URL: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf

3 **Darby SC**, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. *Lancet Oncol* 2005; **6**: 557-565 [PMID: 16054566 DOI: 10.1016/s1470-2045(05)70251-5]

4 **Clarke M**, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; **366**: 2087-2106 [PMID: 16360786]

5 **Jaworski C**, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. *J Am Coll Cardiol* 2013; **61**: 2319-2328 [PMID: 23583253 DOI: 10.1016/j.jacc.2013.01.090]

6 **Stewart FA**, Seemann I, Hoving S, Russell NS. Understanding radiation-induced cardiovascular damage and strategies for intervention. *Clin Oncol (R Coll Radiol)* 2013; **25**: 617-624 [PMID: 23876528 DOI: 10.1016/j.clon.2013.06.012]

7 **Schultz-Hector S**, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? *Int J Radiat Oncol Biol Phys* 2007; **67**: 10-18 [PMID: 17189062]

8 **Andratschke N**, Maurer J, Molls M, Trott KR. Late radiation-induced heart disease after radiotherapy. Clinical importance, radiobiological mechanisms and strategies of prevention. *Radiother Oncol* 2011; **100**: 160-166 [PMID: 20826032 DOI: 10.1016/j.radonc.2010.08.010]

9 **Fajardo LF**, Stewart JR, Cohn KE. Morphology of radiation-induced heart disease. *Arch Pathol* 1968; **86**: 512-519 [PMID: 5681435 DOI: 10.1001/jama.1968.03150100059015]

10 **Fajardo LF**, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. *Lab Invest* 1973; **29**: 244-257 [PMID: 4724850]

11 **Veinot JP**, Edwards WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. *Hum Pathol* 1996; **27**: 766-773 [PMID: 8760008 DOI: 10.1016/s0046-8177(96)90447-5]

12 **Brosius FC**, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. *Am J Med* 1981; **70**: 519-530 [PMID: 6782873]

13 **Carmel RJ**, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. *Cancer* 1976; **37**: 2813-2825 [PMID: 949701 DOI: 10.1002/1097-0142(197606)37: 6]

14 **McGale P**, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, Fornander T, Gigante B, Jensen MB, Peto R, Rahimi K, Taylor CW, Ewertz M. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. *Radiother Oncol* 2011; **100**: 167-175 [PMID: 21752480 DOI: 10.1016/j.radonc.2011.06.016]

15 **Gaya AM**, Ashford RF. Cardiac complications of radiation therapy. *Clin Oncol* (R Coll Radiol) 2005; **17**: 153-159 [PMID: 15900998 DOI: 10.1016/j.clon.2004.09.016]

16 **Bertog SC**, Thambidorai SK, Parakh K, Schoenhagen P, Ozduran V, Houghtaling PL, Lytle BW, Blackstone EH, Lauer MS, Klein AL. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. *J Am Coll Cardiol* 2004; **43**: 1445-1452 [PMID: 15093882 DOI: 10.1016/j.accreview.2004.06.051]

17 **van Nimwegen FA**, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. *JAMA Intern Med* 2015; **175**: 1007-1017 [PMID: 25915855 DOI: 10.1001/jamainternmed.2015.1180]

18 **Aleman BM**, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood* 2007; **109**: 1878-1886 [PMID: 17119114 DOI: 10.1016/0360-3016(85)90314-1]

19 **Lauk S**, Kiszel Z, Buschmann J, Trott KR. Radiation-induced heart disease in rats. *Int J Radiat Oncol Biol Phys* 1985; **11**: 801-808 [PMID: 3980275]

20 **Marks LB**, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S. The incidence and functional consequences of RT-associated cardiac perfusion defects. *Int J Radiat Oncol Biol Phys* 2005; **63**: 214-223 [PMID: 16111592 DOI: 10.1016/j.ijrobp.2005.01.029]

21 **Heidenreich PA**, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. *Heart* 2009; **95**: 252-258 [PMID: 19144884 DOI: 10.1136/hrt.2008.149088]

22 **Darby SC**, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ET, Shore RE. Radiation-related heart disease: current knowledge and future prospects. *Int J Radiat Oncol Biol Phys* 2010; **76**: 656-665 [PMID: 20159360 DOI: 10.1016/j.ijrobp.2009.09.064]

23 **Heidenreich PA**, Hancock SL, Vagelos RH, Lee BK, Schnittger I. Diastolic dysfunction after mediastinal irradiation. *Am Heart J* 2005; **150**: 977-982 [PMID: 16290974 DOI: 10.1016/j.ahj.2004.12.026]

24 **Heidenreich PA**, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. *J Am Coll Cardiol* 2003; **42**: 743-749 [PMID: 12932613 DOI: 10.1016/j.accreview.2003.10.038]

25 **Wethal T**, Lund MB, Edvardsen T, Fosså SD, Pripp AH, Holte H, Kjekshus J, Fosså A. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. *Br J Cancer* 2009; **101**: 575-581 [PMID: 19623176 DOI: 10.1038/sj.bjc.6605191]

26 **Cutter DJ**, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, Janus CP, van Leeuwen FE, Aleman BM. Risk of valvular heart disease after treatment for Hodgkin lymphoma. *J Natl Cancer Inst* 2015; **107**: [PMID: 25713164 DOI: 10.1093/jnci/djv008]

27 **Darby SC**, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013; **368**: 987-998 [PMID: 23484825 DOI: 10.1056/NEJMoa1209825]

28 **Caro-Codón J**, Jiménez-Valero S, Galeote G, Sanchez-Recalde A, Moreno R. Radiation-induced coronary artery disease: Useful insights from OCT. *Int J Cardiol* 2016; **202**: 535-536 [PMID: 26451785 DOI: 10.1016/j.ijcard.2015.09.095]

29 **Imbalzano E**, Trapani G, Creazzo M, Lizio G, Saitta A. Coronary artery disease in radiotherapy. *Int J Cardiol* 2013; **168**: e125-e126 [PMID: 23993725 DOI: 10.1016/j.ijcard.2013.08.037]

30 **Orzan F**, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. *Br Heart J* 1993; **69**: 496-500 [PMID: 8343315 DOI: 10.1136/hrt.69.6.496]

31 **Borst GR**, Sonke JJ, den Hollander S, Betgen A, Remeijer P, van Giersbergen A, Russell NS, Elkhuizen PH, Bartelink H, van Vliet-Vroegindeweij C. Clinical results of image-guided deep inspiration breath hold breast irradiation. *Int J Radiat Oncol Biol Phys* 2010; **78**: 1345-1351 [PMID: 20207496 DOI: 10.1016/j.ijrobp.2009.10.006]

32 **Taunk NK**, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. *Front Oncol* 2015; **5**: 39 [PMID: 25741474 DOI: 10.3389/fonc.2015.00039]

33 **Korpela E**, Liu SK. Endothelial perturbations and therapeutic strategies in normal tissue radiation damage. *Radiat Oncol* 2014; **9**: 266 [PMID: 25518850 DOI: 10.1186/s13014-014-0266-7]

34 **Wynn TA**. Fibrotic disease and the T(H)1/T(H)2 paradigm. *Nat Rev Immunol* 2004; **4**: 583-594 [PMID: 15286725 DOI: 10.1038/nri1412]

35 **Haubner F**, Ohmann E, Pohl F, Prantl L, Strutz J, Gassner HG. Effects of radiation on the expression of adhesion molecules and cytokines in a static model of human dermal microvascular endothelial cells. *Clin Hemorheol Microcirc* 2013; **54**: 371-379 [PMID: 23089880 DOI: 10.3233/CH-2012-1626]

36 **Khaled S**, Gupta KB, Kucik DF. Ionizing radiation increases adhesiveness of human aortic endothelial cells via a chemokine-dependent mechanism. *Radiat Res* 2012; **177**: 594-601 [PMID: 22087741 DOI: 10.1667/rr2557.1]

37 **Stewart JR**, Fajardo LF. Radiation-induced heart disease: an update. *Prog Cardiovasc Dis* 1984; **27**: 173-194 [PMID: 6387801 DOI: 10.1016/0033-0620(84)90003-3]

38 **Pathak R**, Shao L, Ghosh SP, Zhou D, Boerma M, Weiler H, Hauer-Jensen M. Thrombomodulin contributes to gamma tocotrienol-mediated lethality protection and hematopoietic cell recovery in irradiated mice. *PLoS One* 2015; **10**: e0122511 [PMID: 25860286 DOI: 10.1371/journal.pone.0122511]

39 **Danckwardt S**, Hentze MW, Kulozik AE. Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. *J Mol Med* (Berl) 2013; **91**: 1257-1271 [PMID: 23955016 DOI: 10.1007/s00109-013-1074-5]

40 **Wynn TA**. Cellular and molecular mechanisms of fibrosis. *J Pathol* 2008; **214**: 199-210 [PMID: 18161745 DOI: 10.1002/path.2277]

41 **Martin M**, Lefaix J, Delanian S. TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? *Int J Radiat Oncol Biol Phys* 2000; **47**: 277-290 [PMID: 10802350 DOI: 10.1016/s0360-3016(00)00435-1]

42 **May RD**, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. *Cytokine* 2015; **75**: 89-116 [PMID: 26255210 DOI: 10.1016/j.cyto.2015.05.018]

43 **Büttner C**, Skupin A, Reimann T, Rieber EP, Unteregger G, Geyer P, Frank KH. Local production of interleukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: macrophages as a prominent source of interleukin-4. *Am J Respir Cell Mol Biol* 1997; **17**: 315-325 [PMID: 9308918 DOI: 10.1165/ajrcmb.17.3.2279]

44 **Chen J**, Wang Y, Mei Z, Zhang S, Yang J, Li X, Yao Y, Xie C. Radiation-induced lung fibrosis in a tumor-bearing mouse model is associated with enhanced Type-2 immunity. *J Radiat Res* 2016; **57**: 133-141 [PMID: 26703457 DOI: 10.1093/jrr/rrv077]

45 **Xu L**, Xiong S, Guo R, Yang Z, Wang Q, Xiao F, Wang H, Pan X, Zhu M. Transforming growth factor β3 attenuates the development of radiation-induced pulmonary fibrosis in mice by decreasing fibrocyte recruitment and regulating IFN-γ/IL-4 balance. *Immunol Lett* 2014; **162**: 27-33 [PMID: 24996042 DOI: 10.1016/j.imlet.2014.06.010]

46 **Haydont V**, Mathé D, Bourgier C, Abdelali J, Aigueperse J, Bourhis J, Vozenin-Brotons MC. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. *Radiother Oncol* 2005; **76**: 219-225 [PMID: 16046020 DOI: 10.1016/j.radonc.2005.06.029]

47 **Lee CH**, Shah B, Moioli EK, Mao JJ. CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. *J Clin Invest* 2010; **120**: 3340-3349 [PMID: 20679726 DOI: 10.1172/JCI43230]

48 **Grotendorst GR**, Rahmanie H, Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. *FASEB J* 2004; **18**: 469-479 [PMID: 15003992 DOI: 10.1096/fj.03-0699com]

49 **Holmes A**, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. *J Biol Chem* 2001; **276**: 10594-10601 [PMID: 11152469 DOI: 10.1074/jbc.m010149200]

50 **Vozenin-Brotons MC**, Milliat F, Sabourin JC, de Gouville AC, François A, Lasser P, Morice P, Haie-Meder C, Lusinchi A, Antoun S, Bourhis J, Mathé D, Girinsky T, Aigueperse J. Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. *Int J Radiat Oncol Biol Phys* 2003; **56**: 561-572 [PMID: 12738334 DOI: 10.1016/s0360-3016(02)04601-1]

51 **Lipson KE**, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. *Fibrogenesis Tissue Repair* 2012; **5**: S24 [PMID: 23259531 DOI: 10.1186/1755-1536-5-S1-S24]

52 **Desmoulière A**, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. *Am J Pathol* 1995; **146**: 56-66 [PMID: 7856739]

53 **Weigel C**, Schmezer P, Plass C, Popanda O. Epigenetics in radiation-induced fibrosis. *Oncogene* 2015; **34**: 2145-2155 [PMID: 24909163 DOI: 10.1038/onc.2014.145]

54 **Hu B**, Gharaee-Kermani M, Wu Z, Phan SH. Epigenetic regulation of myofibroblast differentiation by DNA methylation. *Am J Pathol* 2010; **177**: 21-28 [PMID: 20489138 DOI: 10.2353/ajpath.2010.090999]

55 **Watson CJ**, Collier P, Tea I, Neary R, Watson JA, Robinson C, Phelan D, Ledwidge MT, McDonald KM, McCann A, Sharaf O, Baugh JA. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. *Hum Mol Genet* 2014; **23**: 2176-2188 [PMID: 24301681 DOI: 10.1093/hmg/ddt614]

56 **Kim YS**, Kang WS, Kwon JS, Hong MH, Jeong HY, Jeong HC, Jeong MH, Ahn Y. Protective role of 5-azacytidine on myocardial infarction is associated with modulation of macrophage phenotype and inhibition of fibrosis. *J Cell Mol Med* 2014; **18**: 1018-1027 [PMID: 24571348 DOI: 10.1111/jcmm.12248]

57 **Kim EH**, Park AK, Dong SM, Ahn JH, Park WY. Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines. *Oncogene* 2010; **29**: 4725-4731 [PMID: 20531302 DOI: 10.1038/onc.2010.223]

58 **Antwih DA**, Gabbara KM, Lancaster WD, Ruden DM, Zielske SP. Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. *Epigenetics* 2013; **8**: 839-848 [PMID: 23880508 DOI: 10.4161/epi.25498]

59 **Weigel C**, Veldwijk MR, Oakes CC, Seibold P, Slynko A, Liesenfeld DB, Rabionet M, Hanke SA, Wenz F, Sperk E, Benner A, Rösli C, Sandhoff R, Assenov Y, Plass C, Herskind C, Chang-Claude J, Schmezer P, Popanda O. Epigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis. *Nat Commun* 2016; **7**: 10893 [PMID: 26964756 DOI: 10.1038/ncomms10893]

60 **Azzam EI**, Jay-Gerin JP, Pain D. Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury. *Cancer Lett* 2012; **327**: 48-60 [PMID: 22182453 DOI: 10.1016/j.canlet.2011.12.012]

61 **Yarnold J**, Brotons MC. Pathogenetic mechanisms in radiation fibrosis. *Radiother Oncol* 2010; **97**: 149-161 [PMID: 20888056 DOI: 10.1016/j.radonc.2010.09.002]

62 **Madamanchi NR**, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. *J Thromb Haemost* 2005; **3**: 254-267 [PMID: 15670030]

63 **Diet A**, Abbas K, Bouton C, Guillon B, Tomasello F, Fourquet S, Toledano MB, Drapier JC. Regulation of peroxiredoxins by nitric oxide in immunostimulated macrophages. *J Biol Chem* 2007; **282**: 36199-36205 [PMID: 17921138 DOI: 10.1074/jbc.m706420200]

64 **Csont T**, Viappiani S, Sawicka J, Slee S, Altarejos JY, Batinić-Haberle I, Schulz R. The involvement of superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. *J Mol Cell Cardiol* 2005; **39**: 833-840 [PMID: 16171809 DOI: 10.1016/j.yjmcc.2005.07.010]

65 **Mollà M**, Gironella M, Salas A, Closa D, Biete A, Gimeno M, Coronel P, Piqué JM, Panés J. Protective effect of superoxide dismutase in radiation-induced intestinal inflammation. *Int J Radiat Oncol Biol Phys* 2005; **61**: 1159-1166 [PMID: 15752897 DOI: 10.1016/j.ijrobp.2004.11.010]

66 **Akpolat M**, Gulle K, Topcu-Tarladacalisir Y, Safi Oz Z, Bakkal BH, Arasli M, Ozel Turkcu U. Protection by L-carnitine against radiation-induced ileal mucosal injury in the rat: pattern of oxidative stress, apoptosis and cytokines. *Int J Radiat Biol* 2013; **89**: 732-740 [PMID: 23510242 DOI: 10.3109/09553002.2013.787176]

67 **Ross CC**, MacLeod SL, Plaxco JR, Froude JW, Fink LM, Wang J, Stites WE, Hauer-Jensen M. Inactivation of thrombomodulin by ionizing radiation in a cell-free system: possible implications for radiation responses in vascular endothelium. *Radiat Res* 2008; **169**: 408-416 [PMID: 18363428 DOI: 10.1667/RR1148.1]

68 **Jeong BK**, Song JH, Jeong H, Choi HS, Jung JH, Hahm JR, Woo SH, Jung MH, Choi BH, Kim JH, Kang KM. Effect of alpha-lipoic acid on radiation-induced small intestine injury in mice. *Oncotarget* 2016; **7**: 15105-15117 [PMID: 26943777 DOI: 10.18632/oncotarget.7874]

69 **Jang SS**, Kim HG, Lee JS, Han JM, Park HJ, Huh GJ, Son CG. Melatonin reduces X-ray radiation-induced lung injury in mice by modulating oxidative stress and cytokine expression. *Int J Radiat Biol* 2013; **89**: 97-105 [PMID: 23046278 DOI: 10.3109/09553002.2013.734943]

70 **Weintraub NL**, Jones WK, Manka D. Understanding radiation-induced vascular disease. *J Am Coll Cardiol* 2010; **55**: 1237-1239 [PMID: 20298931 DOI: 10.1016/j.jacc.2009.11.053]

71 **Halle M**, Gabrielsen A, Paulsson-Berne G, Gahm C, Agardh HE, Farnebo F, Tornvall P. Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. *J Am Coll Cardiol* 2010; **55**: 1227-1236 [PMID: 20298930 DOI: 10.1016/j.jacc.2009.10.047]

72 **Jackson IL**, Chen L, Batinic-Haberle I, Vujaskovic Z. Superoxide dismutase mimetic reduces hypoxia-induced O2\*-, TGF-beta, and VEGF production by macrophages. *Free Radic Res* 2007; **41**: 8-14 [PMID: 17164174 DOI: 10.1080/10715760600913150]

73 **Gabrielli A**, Svegliati S, Moroncini G, Pomponio G, Santillo M, Avvedimento EV. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. *Semin Immunopathol* 2008; **30**: 329-337 [PMID: 18548250 DOI: 10.1007/s00281-008-0125-4]

74 **Gremy O**, Benderitter M, Linard C. Acute and persisting Th2-like immune response after fractionated colorectal gamma-irradiation. *World J Gastroenterol* 2008; **14**: 7075-7085 [PMID: 19084914 DOI: 10.3748/wjg.14.7075]

75 **Kruse JJ**, Strootman EG, Wondergem J. Effects of amifostine on radiation-induced cardiac damage. *Acta Oncol* 2003; **42**: 4-9 [PMID: 12665324 DOI: 10.1080/0891060310002168]

76 **Giordano SH**, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. *J Natl Cancer Inst* 2005; **97**: 419-424 [PMID: 15770005 DOI: 10.1016/s1040-1741(08)70038-1]

77 **Yeboa DN**, Evans SB. Contemporary Breast Radiotherapy and Cardiac Toxicity. *Semin Radiat Oncol* 2016; **26**: 71-78 [PMID: 26617212 DOI: 10.1016/j.semradonc.2015.09.003]

78 **Ahmad SS**, Duke S, Jena R, Williams MV, Burnet NG. Advances in radiotherapy. *BMJ* 2012; **345**: e7765 [PMID: 23212681 DOI: 10.1136/bmj.e7765]

79 **Maraldo MV**, Aznar MC, Vogelius IR, Petersen PM, Specht L. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. *Int J Radiat Oncol Biol Phys* 2013; **85**: 1057-1065 [PMID: 23200817 DOI: 10.1016/j.ijrobp.2012.08.041]

80 **Glanzmann C**, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. *Radiother Oncol* 1998; **46**: 51-62 [PMID: 9488128 DOI: 10.1016/s0167-8140(97)00125-4]

81 **van Leeuwen-Segarceanu EM**, Bos WJ, Dorresteijn LD, Rensing BJ, der Heyden JA, Vogels OJ, Biesma DH. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease. *Cancer Treat Rev* 2011; **37**: 391-403 [PMID: 21333452 DOI: 10.1016/j.ctrv.2010.12.004]

82 **Ha CS**, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith S, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR appropriateness criteria follow-up of Hodgkin lymphoma. *J Am Coll Radiol* 2014; **11**: 1026-1033.e3 [PMID: 25278496 DOI: 10.1016/j.jacr.2014.07.038]

83 **National Comprehensive Cancer Network (NCCN)**. Clinical Practice Guidelines in Oncology. 2015. Available from: URL: http://www.nccn.org/professionals/physician\_gls/pdf/hodgkins.pdf

84 **Lancellotti P**, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, Cosyns B, Coucke P, Dulgheru R, Edvardsen T, Gaemperli O, Galderisi M, Griffin B, Heidenreich PA, Nieman K, Plana JC, Port SC, Scherrer-Crosbie M, Schwartz RG, Sebag IA, Voigt JU, Wann S, Yang PC. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging* 2013; **14**: 721-740 [PMID: 23847385 DOI: 10.1093/ehjci/jet123]

85 **Heidenreich PA**, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT, Hancock SL. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. *J Clin Oncol* 2007; **25**: 43-49 [PMID: 17194904 DOI: 10.1200/jco.2006.07.0805]

86 **Armstrong GT**, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. *J Clin Oncol* 2012; **30**: 2876-2884 [PMID: 22802310 DOI: 10.1200/JCO.2011.40.3584]

87 **Pellerin D**, Sharma R, Elliott P, Veyrat C. Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. *Heart* 2003; **89** Suppl 3: iii9-ii17 [PMID: 14594870 DOI: 10.1136/heart.89.suppl\_3.iii9]

88 **Amundsen BH**, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E, Støylen A, Ihlen H, Lima JA, Smiseth OA, Slørdahl SA. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. *J Am Coll Cardiol* 2006; **47**: 789-793 [PMID: 16487846 DOI: 10.1016/j.jacc.2005.10.040]

89 **Erven K**, Jurcut R, Weltens C, Giusca S, Ector J, Wildiers H, Van den Bogaert W, Voigt JU. Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. *Int J Radiat Oncol Biol Phys* 2011; **79**: 1444-1451 [PMID: 20605341 DOI: 10.1016/j.ijrobp.2010.01.004]

90 **Armstrong GT**, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava D, Griffin BP, Grimm RA, Thomas J, Phelan D, Collier P, Krull KR, Mulrooney DA, Green DM, Hudson MM, Robison LL, Plana JC. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. *J Am Coll Cardiol* 2015; **65**: 2511-2522 [PMID: 26065990 DOI: 10.1016/j.jacc.2015.04.013]

91 **Umezawa R**, Ota H, Takanami K, Ichinose A, Matsushita H, Saito H, Takase K, Jingu K. MRI findings of radiation-induced myocardial damage in patients with oesophageal cancer. *Clin Radiol* 2014; **69**: 1273-1279 [PMID: 25246336 DOI: 10.1016/j.crad.2014.08.010]

92 **Machann W**, Beer M, Breunig M, Störk S, Angermann C, Seufert I, Schwab F, Kölbl O, Flentje M, Vordermark D. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 2011; **79**: 1117-1123 [PMID: 20385449 DOI: 10.1016/j.ijrobp.2009.12.054]

93 **Aquaro GD**, Barison A, Cagnolo A, Todiere G, Lombardi M, Emdin M. Role of tissue characterization by Cardiac Magnetic Resonance in the diagnosis of constrictive pericarditis. *Int J Cardiovasc Imaging* 2015; **31**: 1021-1031 [PMID: 25827067 DOI: 10.1007/s10554-015-0648-4]

94 **Andersen R**, Wethal T, Günther A, Fosså A, Edvardsen T, Fosså SD, Kjekshus J. Relation of coronary artery calcium score to premature coronary artery disease in survivors & gt; 15 years of Hodgkin's lymphoma. *Am J Cardiol* 2010; **105**: 149-152 [PMID: 20102909 DOI: 10.1016/j.amjcard.2009.09.005]

95 **Wethal T**, Nedregaard B, Andersen R, Fosså A, Lund MB, Günther A, Kvaløy S, Fosså SD, Kjekshus J. Atherosclerotic lesions in lymphoma survivors treated with radiotherapy. *Radiother Oncol* 2014; **110**: 448-454 [PMID: 24231235 DOI: 10.1016/j.radonc.2013.10.029]

96 **Tjessem KH**, Bosse G, Fosså K, Reinertsen KV, Fosså SD, Johansen S, Fosså A. Coronary calcium score in 12-year breast cancer survivors after adjuvant radiotherapy with low to moderate heart exposure - Relationship to cardiac radiation dose and cardiovascular risk factors. *Radiother Oncol* 2015; **114**: 328-334 [PMID: 25600105 DOI: 10.1016/j.radonc.2015.01.006]

97 **Chen AB**, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. *J Clin Oncol* 2009; **27**: 5383-5389 [PMID: 19752333 DOI: 10.1200/JCO.2009.22.8460]

98 **Nellessen U**, Zingel M, Hecker H, Bahnsen J, Borschke D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? *Chemotherapy* 2010; **56**: 147-152 [PMID: 20407242 DOI: 10.1159/000313528]

99 **Skyttä T**, Tuohinen S, Boman E, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. *Radiat Oncol* 2015; **10**: 141 [PMID: 26159409 DOI: 10.1186/s13014-015-0436-2]

100 **Haydont V**, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathé D, Bourhis J, Vozenin-Brotons MC. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. *Clin Cancer Res* 2007; **13**: 5331-5340 [PMID: 17875761 DOI: 10.1158/1078-0432.ccr-07-0625]

101 **Fritz G**, Henninger C, Huelsenbeck J. Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents. *Br Med Bull* 2011; **97**: 17-26 [PMID: 21252099 DOI: 10.1093/bmb/ldq044]

102 **Ostrau C**, Hülsenbeck J, Herzog M, Schad A, Torzewski M, Lackner KJ, Fritz G. Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. *Radiother Oncol* 2009; **92**: 492-499 [PMID: 19615773 DOI: 10.1016/j.radonc.2009.06.020]

103 **Shi J**, Wang J, Zheng H, Ling W, Joseph J, Li D, Mehta JL, Ponnappan U, Lin P, Fink LM, Hauer-Jensen M. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. *Blood Coagul Fibrinolysis* 2003; **14**: 575-585 [PMID: 12960612 DOI: 10.1097/00001721-200309000-00010]

104 **Ran XZ**, Ran X, Zong ZW, Liu DQ, Xiang GM, Su YP, Zheng HE. Protective effect of atorvastatin on radiation-induced vascular endothelial cell injury in vitro. *J Radiat Res* 2010; **51**: 527-533 [PMID: 20921821 DOI: 10.1269/jrr.09119]

105 **University of Minnesota - Clinical and Translational Science Institute**. Statin Therapy in Young Adult Survivors of Childhood Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: <https://clinicaltrials.gov/ct2/show/NCT01733953> NLM Identifier: NCT01733953

106 **Ghosh SN**, Zhang R, Fish BL, Semenenko VA, Li XA, Moulder JE, Jacobs ER, Medhora M. Renin-Angiotensin system suppression mitigates experimental radiation pneumonitis. *Int J Radiat Oncol Biol Phys* 2009; **75**: 1528-1536 [PMID: 19931735 DOI: 10.1016/j.ijrobp.2009.07.1743]

107 **Molthen RC**, Wu Q, Fish BL, Moulder JE, Jacobs ER, Medhora MM. Mitigation of radiation induced pulmonary vascular injury by delayed treatment with captopril. *Respirology* 2012; **17**: 1261-1268 [PMID: 22882664 DOI: 10.1111/j.1440-1843.2012.02247.x]

108 **van der Veen SJ**, Ghobadi G, de Boer RA, Faber H, Cannon MV, Nagle PW, Brandenburg S, Langendijk JA, van Luijk P, Coppes RP. ACE inhibition attenuates radiation-induced cardiopulmonary damage. *Radiother Oncol* 2015; **114**: 96-103 [PMID: 25465731 DOI: 10.1016/j.radonc.2014.11.017]

109 **Mihandoost E**, Shirazi A, Mahdavi SR, Aliasgharzadeh A. Can melatonin help us in radiation oncology treatments? *Biomed Res Int* 2014; **2014**: 578137 [PMID: 24900972 DOI: 10.1155/2014/578137]

110 **Shirazi A**, Mihandoost E, Mohseni M, Ghazi-Khansari M, Rabie Mahdavi S. Radio-protective effects of melatonin against irradiation-induced oxidative damage in rat peripheral blood. *Phys Med* 2013; **29**: 65-74 [PMID: 22177584 DOI: 10.1016/j.ejmp.2011.11.00]

111 **Gürses I**, Özeren M, Serin M, Yücel N, Erkal HŞ. Histopathological evaluation of melatonin as a protective agent in heart injury induced by radiation in a rat model. *Pathol Res Pract* 2014; **210**: 863-871 [PMID: 25249491 DOI: 10.1016/j.prp.2014.08.006]

112 **Sieber F**, Muir SA, Cohen EP, Fish BL, Mäder M, Schock AM, Althouse BJ, Moulder JE. Dietary selenium for the mitigation of radiation injury: effects of selenium dose escalation and timing of supplementation. *Radiat Res* 2011; **176**: 366-374 [PMID: 21867430 DOI: 10.1667/rr2456.1]

113 **Avgerinos D**, Rabitnokov Y, Worku B, Neragi-Miandoab S, Girardi LN. Fifteen-year experience and outcomes of pericardiectomy for constrictive pericarditis. *J Card Surg* 2014; **29**: 434-438 [PMID: 24750218 DOI: 10.1111/jocs.12344]

114 **Szabó G**, Schmack B, Bulut C, Soós P, Weymann A, Stadtfeld S, Karck M. Constrictive pericarditis: risks, aetiologies and outcomes after total pericardiectomy: 24 years of experience. *Eur J Cardiothorac Surg* 2013; **44**: 1023-1028; discussion 1028 [PMID: 23761416 DOI: 10.1093/ejcts/ezt138]

115 **DePasquale EC**, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. *J Heart Lung Transplant* 2012; **31**: 1269-1275 [PMID: 23079066 DOI: 10.1016/j.healun.2012.09.018]

116 **Saxena P**, Joyce LD, Daly RC, Kushwaha SS, Schirger JA, Rosedahl J, Dearani JA, Kara T, Edwards BS. Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. *Ann Thorac Surg* 2014; **98**: 2115-2121 [PMID: 25443015 DOI: 10.1016/j.athoracsur.2014.06.056]

117 **Gujral DM**, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. *Heart* 2015; **pii**: heartjnl-2015-308765 [PMID: 26661320 DOI: 10.1136/heartjnl-2015-308765]

118 **Galper SL**, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. *Blood* 2011; **117**: 412-418 [PMID: 20858859 DOI: 10.1182/blood-2010-06-291328]

119 **Crestanello JA**, McGregor CG, Danielson GK, Daly RC, Dearani JA, Orszulak TA, Mullany CJ, Puga FJ, Zehr KJ, Schleck C, Schaff HV. Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy. *Ann Thorac Surg* 2004; **78**: 826-31; discussion 826-31 [PMID: 15337000 DOI: 10.1016/j.athoracsur.2004.04.008]

120 **Möllmann H**, Bestehorn K, Bestehorn M, Papoutsis K, Fleck E, Ertl G, Kuck KH, Hamm C. In-hospital outcome of transcatheter vs. surgical aortic valve replacement in patients with aortic valve stenosis: complete dataset of patients treated in 2013 in Germany. *Clin Res Cardiol* 2016; **105**: 553-559 [PMID: 26830097 DOI: 10.1007/s00392-016-0962-4]

121 **Adams DH**, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med* 2014; **370**: 1790-1798 [PMID: 24678937 DOI: 10.1056/NEJMoa1400590]

122 **Beohar N**, Kirtane AJ, Blackstone E, Waksman R, Holmes D, Minha S, Alli O, Suri RM, Svensson LG, Leon M, Kodali S. Trends in Complications and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement: Experience From the PARTNER Continued Access Registry. *JACC Cardiovasc Interv* 2016; **9**: 355-363 [PMID: 26803420 DOI: 10.1016/j.jcin.2015.10.050]


123 **Schömig K**, Ndrepepa G, Mehilli J, Pache J, Kastrati A, Schömig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. *Catheter Cardiovasc Interv* 2007; **70**: 359-365 [PMID: 17722039 DOI: 10.1002/ccd.21109]

124 **Liang JJ**, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, Prasad A. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. *JACC Cardiovasc Interv* 2014; **7**: 1412-1420 [PMID: 25459527 DOI: 10.1016/j.jcin.2014.05.035]


125 **Handa N**, McGregor CG, Danielson GK, Orszulak TA, Mullany CJ, Daly RC, Dearani JA, Anderson BJ, Puga FJ. Coronary artery bypass grafting in patients with previous mediastinal radiation therapy. *J Thorac Cardiovasc Surg* 1999; **117**: 1136-1142 [PMID: 10343262 DOI: 10.1016/s0022-5223(99)70250-3]

126 **Chang AS**, Smedira NG, Chang CL, Benavides MM, Myhre U, Feng J, Blackstone EH, Lytle BW. Cardiac surgery after mediastinal radiation: extent of exposure influences outcome. *J Thorac Cardiovasc Surg* 2007; **133**: 404-413 [PMID: 17258573 DOI: 10.1016/j.jtcvs.2006.09.041]


**P-Reviewer:** Sergio C, Sicari R, Sun Z, Tan XR **S-Editor:** Ji FF **L-Editor: E-Editor:**




**Figure 1 Severe calcification of proximal aorta and aortic leaflets (arrows) resulting in moderate aortic regurgitation and stenosis.**




**Figure 2 Apical four chamber view of mitral annular calcification (arrow).**



**Figure 3 Severe proximal left anterior descending stenosis (arrow).**



**Figure 4 Radiation injury and the transition from acute inflammation to chronic fibrosis, as mediated by pro-fibrotic cytokines and reactive oxygen species.** Normal tissue (A) becomes inflamed within hours of irradiation (B), and a pro-fibrotic cytokine profile predominates within days-to-weeks (C); D: Represents the chronic state of fibrosis characteristic of radiation injury. O2-: Reactive oxygen species; TNF-α: Tumor necrosis factor alpha; MCP-1: Monocyte chemotactic protein-1; CTGF: Connective tissue growth factor; TGF-β: Tumor growth factor beta.



**Figure 5 Proposed algorithm for cardio-oncologic screening following mediastinal radiotherapy[86].**